市場調査レポート

商品コード

1447809

静注用免疫グロブリンの世界市場規模、シェア、成長分析、用途別、タイプ別、流通チャネル別-産業予測、2024～2031年

Global Intravenous Immunoglobulin Market Size, Share, Growth Analysis, By Application(Hypogammaglobulinemia, CIDP), By Type(IgG, IgM), By Distribution Channel(Hospital Pharmacy, Specialty Pharmacy) - Industry Forecast 2024-2031

出版日: 2024年02月27日 | 発行: SkyQuest

| ページ情報: 英文 157 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 834,697円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 976,438円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,118,179円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.49円

全表示
概要
目次

概要

サンプル依頼リストに入れる

静脈内免疫グロブリンの世界市場規模は、2022年に119億8,000万米ドルと評価され、2023年の128億5,000万米ドルから2031年には225億9,000万米ドルに成長し、予測期間（2024～2031年）のCAGRは7.3%で成長する展望です。

静脈内免疫グロブリン（IVIG）の世界市場は、高齢者人口の増加、免疫不全疾患の増加、IVIG治療の適応外使用の増加、IVIG治療の採用増加などの主要要因によって牽引されています。免疫不全患者の増加は、IVIG供給の創出と必要性を支える重要な力となっています。出血性疾患や慢性炎症性脱髄性多発神経炎（CIDP）を患う患者の増加が、この世界市場の急成長につながっています。IVIG市場は、医療産業への投資が増加した結果、成長しています。さらに、自己免疫疾患やその他の病的状態の有病率の増加は、IVIG製品の市場拡大の主要要因であり、様々な医療ニーズを満たす上でIVIG製品が重要な役割を担っていることを浮き彫りにしています。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

静注用免疫グロブリンの世界市場：用途別

市場概要
低ガンマグロブリン血症
CIDP
免疫不全疾患
先天性エイズ
慢性リンパ性白血病
重症筋無力症
多巣性運動神経障害
ITP
川崎病
ギランバレー症候群
その他

静注用免疫グロブリンの世界市場：タイプ別

市場概要
IgG
IgM
IgA
IgE
IgD

静注用免疫グロブリンの世界市場：流通チャネル別

市場概要
病院薬局
専門薬局
その他

静注用免疫グロブリンの世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

Grifols SA
Octapharma AG
ADMA Biologics
LFB Biotechnologies
Kedrion Biopharma,
Intas Pharmaceuticals.
Biotest AG
BDI Pharma Inc.
Shanghai RAAS Blood Products Co., Ltd.
Takeda Pharmaceutical Company Limited.
CSL Behring
Baxter International Inc.
China Biologics Products Inc.

Product Code: SQMIG35A2611

Global Intravenous Immunoglobulin Market size was valued at USD 11.98 billion in 2022 and is poised to grow from USD 12.85 billion in 2023 to USD 22.59 billion by 2031, growing at a CAGR of 7.3% during the forecast period (2024-2031).

The Global Intravenous Immunoglobulin (IVIG) Market is being driven by some major factors like the growing elderly population, an increase in immunodeficiency disorders, the increased usage of off-label indications for IVIG treatments, and the increasing adoption of IVIG therapies. The increasing number of individuals with immune system deficiencies continues to be the key force behind the creation and need for IVIG supplies. The increasing number of patients dealing with bleeding problems and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is leading to the rapid growth of this global market. The IVIG market is growing as a result of the increased investments made in the healthcare industry. Furthermore, the increasing prevalence of autoimmune diseases and other pathological conditions is a major factor in the growing market for IVIG products, highlighting their critical role in meeting a range of medical needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Intravenous Immunoglobulin Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Intravenous Immunoglobulin Market Segmental Analysis

Four segments make up the worldwide intravenous immunoglobulin market: those based on application, type, distribution channel, and region. The market is divided into several segments based on the application, including Hypogammaglobulinemia, Immunodeficiency Diseases, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal Motor Neuropathy, ITP, Guillain-Barre Syndrome, Kawasaki Disease, and Others. The market is divided into IgG, IgM, IgA, IgE, and IgD segments based on type. The market is divided into Hospital Pharmacy, Specialty Pharmacy, and others segments based on the distribution channel. The market is divided into three regions: North America, Asia Pacific, and Latin America.

Drivers of the Global Intravenous Immunoglobulin Market

One of the main factors driving the growth of the intravenous immunoglobulin market is the widespread adoption of IVIG as the primary treatment option for a variety of uncommon immunological and neurological disorders, most notably primary immunodeficiency (PI) and related diseases. IVIG therapy's widespread adoption as the primary treatment for these illnesses attests to its relevance and effectiveness in controlling them.

Restraints in the Global Intravenous Immunoglobulin Market

Demyelinating illnesses come with a significant financial burden due to diagnosis and treatment costs. One prominent factor impeding the market's growth is the increasing expenses associated with IVIG treatment. IVIG infusions are recurrent, usually given every 3-4 weeks; there are roughly 12-16 sessions per year. IVIG is expected to cost USD 73.89 per gram, for a total anticipated cost of approximately USD 10,000.

Market Trends of the Global Intravenous Immunoglobulin Market

A number of significant trends are influencing the market's evolution and redefining its growth and advancement trajectory. Among them, the most notable trend in the treatment of neurological illnesses is the increasing use of intravenous immunoglobulin (IVIG), which underscores the drug's expanding use outside its conventional applications. Furthermore, a significant change in IVIG therapy is the application of personalized medicine concepts, which allow for the customization of treatments to meet the specific needs of each patient. The development of new immunomodulatory therapies is also reshaping the field and opening up new therapeutic options.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Intravenous Immunoglobulin Market by Application

Market Overview
Hypogammaglobulinemia
CIDP
Immunodeficiency Diseases
Congenital AIDS
Chronic Lymphocytic Leukemia
Myasthenia Gravis
Multifocal Motor Neuropathy
ITP
Kawasaki Disease
Guillain-Barre Syndrome
and Others

Global Intravenous Immunoglobulin Market by Type

Market Overview
IgG
IgM
IgA
IgE
and IgD

Global Intravenous Immunoglobulin Market by Distribution Channel

Market Overview
Hospital Pharmacy
Specialty Pharmacy
and Others

Global Intravenous Immunoglobulin Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

Grifols SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Octapharma AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ADMA Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
LFB Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kedrion Biopharma,
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BDI Pharma Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai RAAS Blood Products Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Behring
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Baxter International Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
China Biologics Products Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments